Non-Current Liabilities
Contingent Consideration Liability (Non-Current)
Biogen Contingent Consideration Liability (Non-Current) increased by 8.3% to $266.90M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 17.0%, from $228.10M to $266.90M. Over 3 years (FY 2020 to FY 2025), Contingent Consideration Liability (Non-Current) shows an upward trend with a 30.7% CAGR.
Analysis
StatementBalance Sheet Statement
SectionNon-Current Liabilities
CategoryCapital Allocation
SignalContext dependent
VolatilityModerate
First reportedQ4 2024
Last reportedQ4 2025
How to read this metric
An increase often indicates successful integration or high performance of acquired assets triggering earn-outs, while a decrease may signal missed targets or the settlement of obligations.
Detailed definition
This represents the long-term portion of obligations to pay additional consideration to sellers in connection with past...
Peer comparison
Standard for companies with active M&A strategies and earn-out structures in purchase agreements.
Metric ID:
contingent_consideration_liability_noncurrentHistorical Data
13 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $226.30M | $210.70M | $209.10M | $202.00M | $197.50M | $195.40M | $221.80M | $221.60M | $228.10M | $237.70M | $242.60M | $246.40M | $266.90M |
| QoQ Change | — | -6.9% | -0.8% | -3.4% | -2.2% | -1.1% | +13.5% | -0.1% | +2.9% | +4.2% | +2.1% | +1.6% | +8.3% |
| YoY Change | — | — | — | — | -12.7% | -7.3% | — | — | — | — | +9.4% | +11.2% | +17.0% |
Range$195.40M – $266.90M
CAGR+5.7%
Avg YoY Growth+3.5%
Median YoY Growth+9.4%
Current Streak5 quarters growth
Product Breakdown
| Segment | Q2 '24 |
|---|---|
| Felzartamab And Izastobart/HIB210 | $640.00M |
| Total | — |
Contingent Consideration Liability (Non-Current) at Other Companies
Frequently Asked Questions
- What is Biogen's contingent consideration liability (non-current)?
- Biogen (BIIB) reported contingent consideration liability (non-current) of $266.90M in Q1 2026.
- How has Biogen's contingent consideration liability (non-current) changed year-over-year?
- Biogen's contingent consideration liability (non-current) increased by 17.0% year-over-year, from $228.10M to $266.90M.
- What is the long-term trend for Biogen's contingent consideration liability (non-current)?
- Over 3 years (2020 to 2025), Biogen's contingent consideration liability (non-current) has grown at a 30.7% compound annual growth rate (CAGR), from $110.30M to $246.40M.
- What does contingent consideration liability (non-current) mean?
- The estimated long-term debt owed to sellers of acquired companies based on future performance targets.